Slide 1: Q1 2023 results
Q1 2023 results Solid results driven by 12% CER net sales growth in non-COVID product groups May 3, 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be, deemed to be forward looking statements within the meaning of Section 27A of the U.S.
Slide 3: Q1 2023 Summary: Solid non-COVID sales growth
Q1 2023 Summary: Solid non-COVID sales growth Net $502 million CER (1) sales +12% CER non-COVID Exceeded outlook for net sales and adjusted EPS vs outlook of ≥ $490 m CER Driven by +12% CER growth in non-COVID product groups Adjusted $0.52 CER (2) Teams executing on our strategy EPS Solid non-COVID
Slide 4: Q1 2023: +12% CER growth in non-COVID product groups
Q1 2023: +12% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -23% -23% (-20% CER) (-20% CER) $628 $628 $485 $485 265 Non-COVID 400 Sample product groups 173 technologies -32% CER +12% CER 434 174 Diagnos
Slide 5: Q1 2023: Five Pillars of Growth driving non-COVID sales gains
Q1 2023: Five Pillars of Growth driving non-COVID sales gains Sample technologies • Double-digit CER growth in non-COVID sales QuantiFERON • 19% CER sales growth with solid sales across all regions QIAstat-Dx • Dynamic sales growth in gastrointestinal and meningitis panels >$685 m NeuMoDx • Growing
Slide 6: Q1 2023: Americas and EMEA lead among regions
Q1 2023: Americas and EMEA lead among regions Americas • U.S., Mexico and Brazil: Double-digit non-COVID CER EMEA sales growth $155 m Americas +10% CER non-COVID $247 m Europe / Middle East / Africa +18% CER non-COVID Q1 2023 • Germany, United Kingdom, France and Italy: Top Net sales performances in
Slide 7: Q1 2023: Investing in the business to deliver sustainable growth
Q1 2023: Investing in the business to deliver sustainable growth Adj. operating income Adj. EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) Targeted investments into key drivers High level of R&D investments into menu expansion for key platforms $232 $207 $0.80 Digitizing QI
Slide 8: Outlook: Q2 and FY 2023
Outlook: Q2 and FY 2023 Q2 2023 outlook FY 2023 outlook Net sales > $490 million CER > $2.05 billion CER Anticipated currency impact Neutral FX impact Neutral FX impact Double-digit CER growth in non-COVID product groups Adjusted EPS ≥ $0.50 CER ≥ $2.10 CER Anticipated currency impact Neutral FX imp
Slide 9: Appendix
_-= : J o ! Ny Appendix sssss
Slide 10: Welcoming a new Supervisory Board member
Welcoming a new Supervisory Board member Steve Rusckowski Joined Supervisory Board and will stand for election at the Annual General Meeting in June 2023 • Most recently served as Chairman, President and Chief Executive Officer of Quest Diagnostics Incorporated • Prior to joining Quest Diagnostics,
Slide 11: Q2 and FY 2023: Outlook and assumptions
Q2 and FY 2023: Outlook and assumptions (As of May 3, 2023) Q2 2023 outlook FY 2023 outlook Net sales > $490 million CER > $2.05 billion CER Anticipated currency impact(1) Neutral FX impact Neutral FX impact Adjusted EPS(2) > $0.50 CER > $2.10 CER Anticipated currency impact(1) Neutral FX impact Neu
Slide 12: Q1 2023: Consolidated Statements of Income (unaudited)
Q1 2023: Consolidated Statements of Income (unaudited) Three months ended Three months ended (In $ thousands, except share data) March 31, 2023 March 31, 2022 Net sales 485,398 628,391 Cost of sales: Cost of sales 161,906 198,118 Acquisition-related intangible amortization 16,016 15,303 Total cost o
Slide 13: 2023: Quarterly sales by product group
2023: Quarterly sales by product group (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 173 -35% -32% Diagnostic solutions(1) 163 -7% -4% Of which Quant
Slide 14: 2023: Sales by non-COVID and COVID-19 product groups
2023: Sales by non-COVID and COVID-19 product groups (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Non-COVID product groups 434 8% 12% COVID-19 product groups 52 -77% -7
Slide 15: 2023: Quarterly sales by product type, customer class and region
2023: Quarterly sales by product type, customer class and region (In $ millions at actual rates / Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 431 -23% -21% revenue
Slide 16: Q1 2023: Reconciliation adjusted results (unaudited)
Q1 2023: Reconciliation adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted sales profit income income tax rate income EPS First quarter 2023 Reported results 485.4 307.5 96.7 108.8 (23.8) 22% 85.0 0.37 Adjustments Business integration, acquisit
Slide 17: Q1 2023: Footnotes for reconciliation adjusted results (unaudited)
Q1 2023: Footnotes for reconciliation adjusted results (unaudited) a) Results for 2023 include costs for acquisition projects, including the acquisition of Verogen Inc. completed on January 4, 2023. It also includes the ongoing integration activities for the acquisition of BLIRT S.A. acquired in May
Slide 18: 2023: Quarterly income statement summary
2023: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Net sales 485.4 Net sales (CER) 501.6 Gross profit 307.5 Gross profit margin 63.3% Adjusted gross profit 326.5 Adjusted gross profit margin 67.3% Operating
Slide 19: Consolidated Balance Sheets
Consolidated Balance Sheets March 31, December 31, March 31, December 31, (In $ thousands, except par value) 2023 2022 (In $ thousands, except par value) 2023 2022 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 359,180 730,669 Current portion of long-term debt 393,24
Slide 20: Maintaining financial flexibility to support business expansion
Maintaining financial flexibility to support business expansion Debt maturity (In $ millions) 601 613 101 113 400 500 500 400 149 75 55 149 18 2023 2024 2025 2027 2029 2032 2035 Convertible notes German Schuldschein (Private placement) May 3, 2023 Q1 2023 Results 20
Slide 21: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, March 31, Three months ended March 31, March 31, (In $ thousands) 2023 2022 (In $ thousands) 2023 2022 Cash flows from operating activities: Cash flows from financing activities: Net income 85,035 155,312 Proceeds from is
Slide 22: Q1 2023: Currency impact
Q1 2023: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q1 2023 0 U.S. dollar 248.3 248.3 50% 0.0 Euro 101.8 106.4 21% 4.7 British pound 24.0 26.6 5% 2.5 Japanese yen 15.0 17.0 3% 2.1 Other currencies 96.3 103.3 21% 7.0
Slide 23: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Annual General Meeting June 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q2 2023 results August 2023 E-mail: phoebe.loh@qiagen.com Q3 2023 results October 2023 Alexandra Koenig Share information Coordinator Invest